Clinical Trials Logo

Filter by:
NCT ID: NCT03630406 Completed - Laser Burn Clinical Trials

Vaginal Elasticity Assessment Before and After Vaginal Carbon Dioxide Laser Treatment.

Start date: October 1, 2018
Phase:
Study type: Observational

Female patients with either stress urinary incontinence (SUI) or vaginal wall weakness and prolapse will be evaluated for vaginal elasticity using vaginal tactile imaging both before and after Carbon Dioxide laser treatment.

NCT ID: NCT03629184 Completed - Influenza Clinical Trials

Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms

Start date: November 20, 2018
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety, pharmacokinetics, and efficacy of baloxavir marboxil compared with oseltamivir in a single influenza episode in otherwise healthy pediatric participants (i.e., 1 to <12 years of age) with influenza-like symptoms.

NCT ID: NCT03627767 Completed - Dermatitis, Atopic Clinical Trials

Study to Investigate Efficacy and Safety of PF-04965842 in Subjects Aged 12 Years and Over With Moderate to Severe Atopic Dermatitis With the Option of Rescue Treatment in Flaring Subjects

Start date: June 11, 2018
Phase: Phase 3
Study type: Interventional

B7451014 is a Phase 3 study to investigate PF-04965842 in patients aged 12 years and over with a minimum body weight of 40 kg who have moderate to severe atopic dermatitis. Subjects responding well to an initial open-label 12 week treatment of PF-04965842 (200 mg) taken orally once daily (QD) will be identified and randomized in a double-blind manner to receive 200 mg QD PF-04965842, 100 mg QD PF-04965842, or QD placebo. Efficacy and safety of 2 doses of PF-04965842 will be evaluated relative to placebo over 40 weeks. Subjects experiencing significant worsening of their symptoms, i.e., protocol-defined flare, enter 12 weeks rescue treatment and receive 200 mg PF-04965842 together with a marketed topical medicine. Eligible patients will have the option to enter a long-term extension study after completing the initial 12 week treatment, the 12 week rescue treatment, and the 40 week blinded treatment.

NCT ID: NCT03625440 Completed - Waterpipe Smoking Clinical Trials

Acute Effects of Waterpipe Smoking on Cognitive Measures and Cardiorespiratory Parameters

Start date: August 2016
Phase: N/A
Study type: Interventional

Title: Acute effects of waterpipe smoking (WPS) on cognitive measures and cardiorespiratory parameters Objectives: To evaluate the acute effect of one cession of water pipe smoking on: 1. executive functions which evaluated by cognitive tests administered included the digit span subtest Wechsler Adult Intelligence Scale (WAIS)-version III hebrew battery, and the Paced Auditory Serial Addition Test (PASAT) 2. Cardiorespiratory parameters included vital signs, spirometry parameters and lung clearance index (LCI) value 3. serum carboxyhemoglobin, nicotine, and cytokines Design: Prospective study evaluating these parameters before and after 30 minutes of water pipe smoking (WPS). Sample size: 55 participants (35 study group, 20 control group) Participant selection: Adults subjects who regularly smoke water pipe. Intervention: Each subject will undergo evaluation including cognitive tests, Cardiorespiratory parameters, carboxy- hemoglobin levels, nicotine levels, serum cytokines levels. All measurements will be evaluated before and after one cession of 30 minutes water pipe smoking

NCT ID: NCT03622580 Completed - Clinical trials for Diabetic Macular Edema

A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)

Start date: September 5, 2018
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy, safety, and pharmacokinetics of faricimab administered at 8-week intervals or as specified in the protocol following treatment initiation, compared with aflibercept once every 8 weeks (Q8W), in participants with diabetic macular edema (DME).

NCT ID: NCT03621280 Completed - Cushing Syndrome Clinical Trials

Open-label Treatment in Cushing's Syndrome

OPTICS
Start date: January 7, 2019
Phase: Phase 3
Study type: Interventional

This is a long-term, open-label extension study of levoketoconazole in subjects with endogenous Cushing's Syndrome.

NCT ID: NCT03620747 Completed - Asthma Clinical Trials

Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)

Start date: August 30, 2018
Phase: Phase 3
Study type: Interventional

Primary Objective: To describe the long-term safety of dupilumab in treatment of participants with moderate to severe asthma who completed the previous asthma clinical trial (TRAVERSE-LTS12551).

NCT ID: NCT03618875 Completed - Pain Clinical Trials

Reduction of Post Intravitreal Injection Bleeding and Pain by Ice

Start date: January 1, 2017
Phase: N/A
Study type: Interventional

Intravitreal injections are an efficient method for delivering intraocular therapeutic agents in numerous ophthalmologic diseases. However, side effects, such as pain and subconjunctival hemorrhage remain a major concern. Prevention or alleviation of those side effects might shorten the healing duration and improve patients' quality of life.

NCT ID: NCT03611751 Completed - Psoriasis Clinical Trials

An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis

POETYK-PSO-2
Start date: July 26, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo and a currently available treatment in participants with moderate to severe plaque psoriasis.

NCT ID: NCT03610958 Completed - Obesity Clinical Trials

Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss.

Start date: September 4, 2014
Phase: N/A
Study type: Interventional

Study design to demonstrate the safety and performance of the Epitomee Device